Pharm Dur Acquired By Acs
ACS Strengthens Market Position with Pharm/DUR Acquisition, Enhancing Pharmaceutical Auditing Capabilities and Ensuring Seamless Business Exit for Sellers
ACS Strengthens Market Position with Pharm/DUR Acquisition, Enhancing Pharmaceutical Auditing Capabilities and Ensuring Seamless Business Exit for Sellers
Affiliated Computer Services Inc. (ACS), a leading business process outsourcing company, announced the acquisition of Pharm/DUR Inc.
The acquisition reinforces ACS’s presence in the pharmaceutical auditing sector, enhancing its capabilities in identifying inaccuracies in pharmacy transactions.
Dallas-based ACS (NYSE: ACS) did not disclose the financial terms of the company sale. However, the move strengthens ACS’s audit and verification business, which began five years earlier with the acquisition of Heritage Information Systems. By integrating Pharm/DUR, ACS aims to deliver enhanced auditing solutions to public and private healthcare systems.
Pharm/DUR, headquartered in Philadelphia, has built a robust nationwide auditing platform designed to detect discrepancies, overpayments, and fraudulent transactions. A key asset brought into the acquisition is AUDITrack, a proprietary tool that identifies potential errors in pharmaceutical transactions.
For the 12-month period ending in April 2009, Pharm/DUR reported $6 million in revenue, highlighting its strong market presence and financial performance.
Christopher T. Deelsnyder, Senior Vice President and Managing Director of ACS Government Healthcare Solutions, reassured stakeholders that Pharm/DUR’s employees would remain unaffected by the business exit. This ensures continuity in service quality and operational efficiency.
The shareholders of Pharm/DUR expressed their appreciation for the guidance received during the transaction. They credited the seamless process to expert transaction support, which helped them navigate challenges, secure a higher sale price, and ultimately achieve their financial goals.
Their heartfelt testimonial reflects the significance of expert advisory services in facilitating a successful business sale. They emphasized the life-changing impact of the acquisition, allowing them to pursue long-held aspirations post-sale.
The acquisition of Pharm/DUR marks a significant milestone for ACS, reinforcing its commitment to improving pharmaceutical auditing services. With enhanced capabilities and a strengthened market position, ACS is poised for continued growth in the healthcare sector.
Mark Sapsford led the M&A transaction advising exiting shareholders Tony Spay and Ron Nighswander. Price and terms are undisclosed.
More healthcare technology M&A news: UK's Quicksilva sold to Canada's Harris Corporation
"Thank you for the transaction you completed for both Ron and me.
"Right from the start, you told us how the process would work and what we needed to prepare for each stage.
"You were there by our sides all the way and even when you ended up in the hospital for a week we knew you were still taking calls on our transaction. You attended every meeting in each of the phases and prepared us for what the next stage would be, whilst a business sale is never easy, I don’t believe we would have completed a sale without your help and personal attention.
"We were unfortunate to not sell to the first purchaser we went into exclusivity with and you were incredibly patient with us during this phase. Your determination to progress the sale process and commitment to a positive outcome delivered a different acquirer who went on to pay a significantly higher price.
"Ron and I were incredibly thankful for all the work you did for us in achieving the price we eventually sold the business for.
"We have been able to do all the things we had dreamed of and have felt incredibly liberated by the sale."
Anthony Spay
Co-founder & CEO, Pharm DUR Inc (USA)
Let's chat about your future plans. We can help you get clear on where you and your business are going.